1.A novel approach in treating phantom limb pain using Erector Spinae Plane Block
Karmi Margaret G. Marcial ; Maria Victoria Rosario V. Arcilla
Acta Medica Philippina 2024;58(9):44-47
Phantom limb pain (PLP) is difficult to control, and patients frequently exhibit inadequate relief from medications or encounter unbearable side effects. We present here a novel application of erector spinae plane (ESP) block to manage PLP. Our patient is a 23-year-old, college student, diagnosed with high-grade osteosarcoma of the right humerus who underwent a right shoulder disarticulation. He reported PLP despite multimodal analgesia postoperatively. An ESP block using a high-frequency linear probe ultrasound was performed. A G23 spinal needle was advanced inplane toward the right T3 transverse process. After negative aspiration, 20 mL of therapeutic solution containing bupivacaine 0.25%, lidocaine 1%, epinephrine 5 mcg/ml, and 40 mg methylprednisolone was injected. After the procedure, the patient reported that his PLP went down to NRS 1/10. He consistently reported to have an NRS score of 0-1/10 on succeeding consultations despite discontinuation of opioid and pregabalin. In literature, ESP block has been used as a regional technique for shoulder disarticulation surgery and other neuropathic pain conditions, but no account has shown its use for PLP treatment. The procedure was successfully done to alleviate the upper extremity phantom limb pain, significantly reduce analgesic requirements, and improve tolerance of physical therapy and overall quality of life.
Phantom Limb
;
Cancer Pain
2.Association between knowledge of resident physicians with practice of morphine use among government hospitals
Irene Veron T. Bernardo-Chico ; Jenell Y. Oczon-Naldo
The Filipino Family Physician 2018;56(4):182-189
Introduction:
The efficacy of opioids for cancer pain has been proven. However, opioids specifically Morphine usage for
cancer pain relief among resident physicians is still low. One of the major contributing factors to inadequate pain control is the healthcare provider’s lack of knowledge about cancer and non- cancer pain. Hence, this study was done to assess and identify the level of knowledge and practice of the physicians on opioid use for chronic pain.
Methods:
A validated questionnaire on knowledge and practice was given to the resident physicians in training in 2 government hospitals in region 1 namely Ilocos Training and Regional Medical Center (ITRMC) and Mariano Marcos Memorial Hospital and Medical Center (MMMH&MC). Descriptive statistics were used to analyze demographics, overall knowledge and practice on morphine use among resident physicians and inferential statistics were used to test for comparative study between the two different institutions.
Results:
A total of 83 respondents, 50 from ITRMC and 33 from MMMH&MC, 56 of which were females and 27 were males showed that the overall knowledge of resident physicians elucidates that out of 11 questions asked, they acquired half normative or mean scores of 6.44 in ITRMC and 5.61 in MMMH&MC, respectively. Resident physicians in both government hospitals do not use or give morphine use acquiring more than half, 27 out of 50 or 54.0% in ITRMC and 23 out of 29 or 79.3% in MMMH&MC.
Conclusion
The results showed that the level of understanding and knowledge on morphine use among resident physicians from both government hospitals is inadequate. Thus, their limited knowledge hinders the utilization of morphine use.
Knowledge
;
Analgesics, Opioid
;
Cancer Pain
3.Prevalence of depressive symptoms among adult chronic cancer pain patients of the Philippine General Hospital - Pain Clinic.
Dominic D. Villa ; Mark David S. Yu
Acta Medica Philippina 2022;56(18):12-16
Objective. Chronic cancer pain and depressive symptoms are interrelated in clinical settings. As local data is lacking, this study aimed to determine the prevalence of depressive symptoms among chronic cancer pain patients seen at the Philippine General Hospital - Pain Clinic (PGH-PC).
Methods. In this retrospective, descriptive, cross-sectional study, data were collected from the charts of chronic
cancer pain patients seen at the PGH-PC. The Pain Clinic Self-Report Questionnaire (SRQ) tool was used to assess depressive symptoms. Clinico-demographic data were obtained and analyzed using descriptive statistics.
Results. Of the 129 patients included in the study, 61 had depressive symptoms corresponding to a prevalence of 47.29% (38.72 - 56.01 95% CI). Overall, a more significant number of patients included in the study were female, belonged to age 41-50, were married, attained secondary education, and were unemployed. Demographically, there were no statistically significant differences between chronic cancer pain patients who exhibited depressive symptoms and those who did not. The cancer type showed a statistically significant difference among those cancer patients with or without depressive symptoms (p = 0.016). Breast and gynecologic malignancies comprised more than half of the patients studied. Neither the cancer stage nor the pain scores had a statistically significant difference among those cancer patients with or without symptoms of depression.
Conclusion. Almost 1 in every two chronic cancer pain patients studied had depressive symptoms. Routine screening of patients for depressive symptoms could identify patients and may initiate interventions in this vulnerable population
Prevalence ; Depression ; Cancer Pain ; Chronic Pain
4.A clinical study of palliative treatment for cancer pain and uncontrolled symptoms in patients with recurrent gastric cancer
Tatsuhiko HAYASHI ; Fuyuki ASAMI ; Satoru HATAKEYAMA ; Yuichi MURAYAMA ; Haruo SHIMIZU
Journal of the Japanese Association of Rural Medicine 2003;52(5):817-822
We investigated the current status and problems of cancer pain relief, sedation for cancer pain and uncontrolled symptoms in patients with recurrent gastric cancer. The subjects of this study were 59 patients with recurrent gastric cancer undergoing palliative treatment in the Department of Surgery of our hospital. We retrospectively examined the modality of cancer pain relief, use of sedation and the reason for sedation. Outpatient treatment lasted 0-682 days (mean ; 195.3 days) and hospitalization 1-117 days(mean ; 32.1 days). Nonsteroidal antiinflammatory drugs were used for all patients. Morphine was administered to 50 patients (84.7%). Analgesic effects were seen in all patients. No servere adverse events occurred. Sedation was used in 33 (55.9%) for general fatigue (28) and/or restlessness (17). We concluded that analgesia was sufficient and safe with nonsteroidal antiphlogistic and pharmaceutical morphines, but about half of the cases required sedation.
cancer pain
;
Sedation procedure
;
Gastric cancer recurrent
;
therapeutic aspects
;
symptoms <1>
5.Efficacy of Continuous Prevention of Injury Combined with Interfereuce of Pain on Enhancement of Physical Safety and Pain Control in Patients with Multiple Myeloma.
Cai-Ying ZHANG ; Shuang-Hua WANG ; Mei-Jie YANG
Journal of Experimental Hematology 2019;27(6):1901-1906
OBJECTIVE:
To analyze the efficacy of continuous prevention injury combined with interference of pain on enhomcement of physical safety inside and outside hospital and pain control in patients with multiple myeloma (MM).
METHODS:
Two hundred and thirty-three MM patients admitted in our hospital from January 2016 to December 2017 were divided into 2 group according to odd-even number of hospitalization: routine nursing group (odd number) and combined nursing group (ever number). 119 patients in routine nursing group were given routine nursing, 114 patients in combined nursing group were given combined nursing consisting of continuous prevention of injury combined with interference of pain. The safety event incidence, pain relief, life quality and mental status of patients in 2 groups were compared.
RESULTS:
The incidence of accidental injuries and disease damages in combined nursing group was significantly lower than that in routine nursing group (3.51% and 4.29% vs 11.76% and 12.61%) (P<0.05). The numeric rating scale (NRS) pain score on the day of hospitalization was not significantly different between 2 groups (P>0.05), after interference, the NRS score and the six-point behavior score in combined nursing group were superior to those in routine nursing group (P<0.05). Before interference, the life quality scores were not significantly different between 2 groups (P>0.05), after interference, the some indicators of life quality in 2 groups were impromoved, the scores of physical function, role function, coguitive function, emotional function, and social function of patients in combined nursing group were superior to those in routine nursing group, the scores related with fatigue, nausea and vomiting, pain, loss of appetite, insomnia and overall health status of patients in combined nursing group were superior to those in routine nursing group (P<0.05). Before interference, there were no significant difference in scores of HAMA scale and HAMD scale between 2 groups (P>0.05), after interference, the scores of HAMA scale and HAMD scale in 2 groups both decreased, but the scores of above-mentioned scales in combined nursing group was lower than those in routine nursing group (P<0.05).
CONCLUSION
The Continuous prevention of injury combined with interference of pain shows the better safety of inside and outside hospital and good efficacy of pain control for MM patients.
Cancer Pain
;
Humans
;
Multiple Myeloma
;
Nausea
;
Quality of Life
;
Vomiting
6.Cancer pain, a serious threat to patientsmemory.
Xue-Yan OUYANG ; Chao YANG ; Zhen ZHU ; Jing LI ; Yun-Heng SUN ; Gang DING ; Yong-Hua JI ; Feng JIANG
Acta Physiologica Sinica 2019;71(2):343-349
A large number of cancer patients suffer from pain. Growing evidence suggested that pain might be a serious risk factor for cancer patients. The shared modulators and modulation pathways between neural system and tumor cells, such as various neurotransmitters and neurogenic cytokines, provide essential basis for the effect of pain on tumor. In this article, we reviewed some possible mechanism of this process from two aspects: the systematic regulation of central nervous system on endocrine and immunity, and the regional regulation of peripheral nerves on tumor cells. The aim of this review is to provide more innovative knowledge about pain and cancer and to emphasize the importance of anti-pain in the therapy of cancer.
Cancer Pain
;
physiopathology
;
Central Nervous System
;
Humans
;
Memory
;
Neurotransmitter Agents
;
Pain
;
Peripheral Nerves
7.Intradermal needling combined with heat-sensitive moxibustion for moderate to severe cancer pain.
Jin-Feng JI ; Xiao-Xia GE ; Chun-Ming XU ; Yang JIANG ; Jun-Hong GU ; Guo-Hua WEI ; Ji-Shu GU ; Yong-Jie SHI ; Xue-Jiao NI
Chinese Acupuncture & Moxibustion 2021;41(7):725-729
OBJECTIVE:
To observe the effect of intradermal needling combined with heat-sensitive moxibustion for moderate to severe cancer pain.
METHODS:
A total of 60 patients with moderate to severe cancer pain were randomly divided into an observation group and a control group,30 cases in each one. In the control group,opioids were taken to relief pain according to the three-step analgesic method of World Health Organization. On the base of the treatment as the control group, intradermal needling combined with heat-sensitive moxibustion were applied at Neiguan (PC 6), Hegu (LI 4), Zusanli (ST 36), Taichong (LR 3), etc. in the observation group, 14 days of treatment were required. The equivalent morphine consumption at the first day and whole course, the scores of cancer quality of life questionnaire-C30 (QLQ-C30) and Hamilton anxiety scale before and after treatment, and the adverse reaction rate were compared in the two groups. The total analgesic effective rate was evaluated.
RESULTS:
The total analgesic effective rate was 93.3% (28/30) in the observation group, higher than 73.3% (22/30) in the control group (
CONCLUSION
Intradermal needling combined with heat-sensitive moxibustion can reduce the dose of opioids, improve the quality of life, relief the anxiety in patients with moderate to severe cancer pain, and reduce the incidence of common adverse reaction of opioids.
Acupuncture Points
;
Cancer Pain/therapy*
;
Hot Temperature
;
Humans
;
Moxibustion
;
Neoplasms/therapy*
;
Pain
;
Quality of Life
;
Treatment Outcome
8.Miao medicinal crossbow acupuncture therapy as adjuvant treatment for lung cancer pain: a randomized controlled trial.
Hui CHEN ; Wen-Yu WU ; Zhen-Ming XIE ; Zhu YANG ; Bing YANG ; Dong-Xin TANG
Chinese Acupuncture & Moxibustion 2023;43(3):322-326
OBJECTIVE:
To observe the clinical efficacy of Miao medicinal crossbow acupuncture therapy as adjuvant treatment for lung cancer pain based on oxycodone hydrochloride extended-release tablet.
METHODS:
A total of 60 patients with lung cancer pain were randomized into an observation group (30 cases, 1 case dropped off) and a control group (30 cases). In the control group, oxycodone hydrochloride extended-release tablet was given orally, 10 mg a time, once every 12 hours. On the basis of the treatment in the control group, Miao medicinal crossbow acupuncture therapy was applied once every other day in the observation group. The treatment of 14 days was required in the two groups. Before and after treatment, the numerical rating scale (NRS) score, number of break-out pain and Karnofsky performance status (KPS) score were observed in the two groups. The equivalent oxycodone consumption and rate of adverse reactions were recorded, the analgesic effect was evaluated in the two groups.
RESULTS:
Compared before treatment, the NRS scores and number of break-out pain were decreased while the KPS scores were increased after treatment in the two groups (P<0.01). After treatment, the NRS score and number of break-out pain in the observation group were lower than the control group (P<0.01), the KPS score in the observation group was higher than the control group (P<0.05). The equivalent oxycodone consumption of whole course and the rate of adverse reactions i.e. constipation, drowsiness, nausea and vomiting in the observation group were lower than the control group (P<0.05). The analgesic effect rate was 93.1% (27/29) in the observation group, which was superior to 63.3% (19/30) in the control group (P<0.05).
CONCLUSION
On the basis of oxycodone hydrochloride extended-release tablet, Miao medicinal crossbow acupuncture therapy as adjuvant treatment can effectively relieve the pain degree, reduce the number of break-out pain and improve the health status and quality of life in patients with lung cancer pain, enhance the efficacy of medication and reduce its adverse reactions.
Humans
;
Cancer Pain
;
Oxycodone
;
Quality of Life
;
Lung Neoplasms
;
Pain
;
Acupuncture Therapy
;
Adjuvants, Immunologic
;
Lung
;
Analgesics
9.Single-incision Laparoscopic Gastrectomy for Gastric Cancer.
Journal of Gastric Cancer 2017;17(3):193-203
The implementation of national cancer screening has increased the detection rates of early gastric cancer (EGC) in Korea. Since the successful introduction of laparoscopic gastrectomy for gastric cancer in the early 1990s, this technique has demonstrated improved short-term outcomes without compromising long-term oncologic results. It is associated with reduced pain, shorter hospitalization, reduced morbidity rates, better cosmetic outcomes, and equivalent mortality rates as those for open surgery. Laparoscopic gastrectomy improves patients' quality of life (QOL) and provides favorable prognosis. Single-incision laparoscopic gastrectomy (SILG) is one extremely minimally invasive method, theoretically offering improved cosmetic results, less postoperative pain, and earlier recovery after surgery than conventional multiport laparoscopic gastrectomy. In this context, SILG is thought to be an optimal method to promote and maximize patients' QOL in the acute postoperative phase. However, the technical difficulties of this procedure have limited its use. Since the first report describing single-incision distal gastrectomy in 2011, only 16 studies to date have evaluated SILG. Most of these studies have focused on the technical feasibility and safety of SILG because its long-term outcomes have not been reported. This article reviews the advantages and limitations of SILG.
Early Detection of Cancer
;
Gastrectomy*
;
Hospitalization
;
Korea
;
Laparoscopy
;
Methods
;
Mortality
;
Pain, Postoperative
;
Prognosis
;
Quality of Life
;
Stomach Neoplasms*
10.Phase I Study of CKD-516, a Novel Vascular Disrupting Agent, in Patients with Advanced Solid Tumors.
Do Youn OH ; Tae Min KIM ; Sae Won HAN ; Dong Yeop SHIN ; Yun Gyoo LEE ; Keun Wook LEE ; Jee Hyun KIM ; Tae You KIM ; In Jin JANG ; Jong Seok LEE ; Yung Jue BANG
Cancer Research and Treatment 2016;48(1):28-36
PURPOSE: CKD-516 is a newly developed vascular disrupting agent. This phase I dose-escalation study of CKD-516 was conducted to determine maximum-tolerated dose (MTD), safety, pharmacokinetics, and preliminary antitumor efficacy in patients with advanced solid tumors. MATERIALS AND METHODS: Patients received CKD-516 intravenously on D1 and D8 every 3 weeks, in a standard 3+3 design. Safety was evaluated by National Cancer Institute Common Terminology Criteria for Adverse Events ver. 4.02 and response was assessed by Response Evaluation Criteria in Solid Tumor ver. 1.1. RESULTS: Twenty-three patients were treated with CKD-516 at seven dosing levels: 1 mg/m2/day (n=3), 2 mg/m2/day (n=3), 3.3 mg/m2/day (n=3), 5 mg/m2/day (n=3), 7 mg/m2/day (n=3), 9 mg/m2/day (n=6), and 12 mg/m2/day (n=2). Mean age was 54 and 56.5% of patients were male. Two dose-limiting toxicities, which were both grade 3 hypertension, were observed in two patients at 12 mg/m2/day. The MTD was determined as 12 mg/m2/day. Most common adverse events were gastrointestinal adverse events (diarrhea, 34.8% [30.4% grade 1/2, 13.0% grade 3]; nausea, 21.7% [all grade 1/2]; vomiting, 21.7% [all grade 1/2]), myalgia (17.4%, all grade 1/2), and abdominal pain (21.7% [21.7% grade 1/2, 4.3% grade 3]). The pharmacokinetic study showed the dose-linearity of all dosing levels. Among 23 patients, six patients (26.1%) showed stable disease. Median progression-free survival was 39 days (95% confidence interval, 37 to 41 days). CONCLUSION: This study demonstrates feasibility of CKD-516, novel vascular disrupting agent, in patients with advanced solid tumor. MTD of CKD-516 was defined as 12 mg/m2/day on D1 and D8 every 3 weeks.
Abdominal Pain
;
Disease-Free Survival
;
Humans
;
Hypertension
;
Male
;
Myalgia
;
National Cancer Institute (U.S.)
;
Nausea
;
Pharmacokinetics
;
Vomiting